Closely-held Scientus Pharma received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art commercial production facility in Whitby, Ontario.
“At Scientus Pharma, our main purpose is to provide patients and physicians with a standardized, predictable and effective medicine,” Har Grover, chairman and CEO, said in a statement.
“We have developed a proprietary continuous flow extraction platform to produce consistent batch profiles of oils and soft gel capsules with 100% decarboxylation,” he added. “This will allow us to generate product predictability, to increase patient safety and to help health care practitioners improve dosing guidelines.”
Mr. Grover said that at a manufacturing capacity of up to 200,000 cannabis soft gel capsules an hour, “we believe that our in-house production capabilities are unrivalled.”
That, combined with the company’s ability to produce cannabis-infused gelatins into a product that is more than 99% activated for THC and CBD, “makes us unique in the cannabis industry,” he added. “Our production platform can also be major value-add in the beverage sector.”
In addition to receiving a production license, Scientus said it has had its pre-sales audit, the final step prior to receiving its sales license from Health Canada.
Scientus also said it has been granted a notice of allowance from the U.S. Patent and Trademark Office on the first of its patent applications. The company has several other patent applications pending that, if granted, would provide additional protection for its formulation and extraction technologies.
